Skip to main content

Table 6 Summary of results of the sensitivity analyses

From: Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece

Sensitivity analysis Liraglutide 1.2 mg vs. sitagliptin Liraglutide 1.8 mg vs. exenatide BID
  Difference in QALYs Difference in costs [€] ICER [€ per QALY gained] Difference in QALYs Difference in costs [€] ICER [€ per QALY gained]
Base case 0.19 (0.16) 2797 (1468) 15101 0.19 (0.16) 1302 (1492) 6818
Model time horizon:       
 30 years 0.18 (0.15) 2857 (1428) 15767 0.18 (0.15) 1380 (1541) 7874
 20 years 0.12 (0.11) 2946 (1186) 23797 0.12 (0.12) 1531 (1218) 12531
 10 years 0.06 (0.06) 3569 (791) 61595 0.05 (0.06) 2306 (774) 43977
 5 years 0.04 (0.02) 3787 (452) 106618 0.03 (0.03) 2458 (516) 84503
Discount rate:       
 0% 0.34 (0.31) 2319 (2759) 6776 0.36 (0.30) 552 (2767) 1529
 6% 0.13 (0.11) 2879 (1057) 22353 0.13 (0.11) 1529 (1081) 11754
Costs of complications:       
 Increased by 10% 0.19 (0.16) 2694 (1605) 14541 0.19 (0.16) 1074 (1630) 5625
 Decreased by 10% 0.19 (0.16) 2902 (1323) 15666 0.19 (0.16) 1531 (1355) 8020
Physiological parameters:       
 HbA1c 95% upper limit 0.23 (0.15) 2411 (1565) 10334 0.26 (0.16) 798 (1500) 3101
 HbA1c 95% lower limit 0.14 (0.16) 3270 (1557) 23725 0.12 (0.16) 1947 (1500) 15961
 UKPDS creep of HbA1c for 5 years 0.10 (0.15) 3362 (1597) 32756 0.10 (0.15) 1922 (1613) 18940
 SBP 95% upper limit 0.20 (0.16) 2784 (1517) 14086 0.21 (0.15) 1142 (1500) 5380
 SBP 95% lower limit 0.18 (0.15) 2897 (1468) 16246 0.19 (0.15) 1375 (1444) 7327
 Lipid 95% upper limit 0.22 (0.16) 2744 (1541) 12693 0.22 (0.15) 1162 (1605) 5373
 Lipid 95% lower limit 0.17 (0.16) 2781 (1492) 16577 0.16 (0.15) 1459 (1525) 9400
 BMI 95% upper limit 0.20 (0.15) 2810 (1500) 13823 0.20 (0.17) 1274 (1484) 6231
 BMI 95% lower limit 0.18 (0.16) 2820 (1500) 16030 0.18 (0.16) 1269 (1460) 7263
 BMI benefit maintained 0.25 (0.15) 2759 (1476) 11105 0.21 (0.16) 1312 (1492) 6408
Hypoglycaemia:       
 No hypo disutility 0.19 (0.16) 2797 (1468) 14867 0.18 (0.16) 1302 (1492) 7272
 Disutility of −0.0052 for all hypos 0.19 (0.16) 2797 (1468) 15118 0.19 (0.16) 1302 (1492) 6699
Treatment duration:       
 7 years 0.20 (0.15) 3941 (1428) 19773 0.20 (0.17) 2114 (1557) 10458
 3 years 0.19 (0.17) 1329 (1500) 7123 0.19 (0.16) 275 (1460) 1480
Greek cohort data 0.12 (0.14) 3008 (1775) 24355 0.12 (0.15) 1586 (1928) 13424
52 week clinical data 0.22 (0.17) 2309 (1508) 10564    
Liraglutide delayed by 1 year 0.12 (0.16) 2340 (1581) 19960 - - -
Liraglutide 1.2 mg cost &:       
 100% of 1.8 mg efficacy - - - 0.19 (0.16) −1473 (1492) Lira. Dominant
 90% of 1.8 mg efficacy - - - 0.14 (0.15) −1016 (1500) Lira. Dominant
 80% of 1.8 mg efficacy - - - 0.08 (0.15) −625 (1613) Lira. Dominant
 70% of 1.8 mg efficacy - - - 0.02 (0.15) −126 (1525) Lira. Dominant
  1. Data are mean (SD). QALY = quality-adjusted life year; € = 2013 Euros; ICER = incremental cost-effectiveness ratio; HbA1c = glycated haemoglobin; UKPDS = United Kingdom Prospective Diabetes Study; SBP = systolic blood pressure; BMI = body mass index; Hypo = hypoglycaemic event; Lira = Liraglutide.